Unlike most areas of clinical medicine, variations in drug effect by ethnicity are biologically plausible: Differences in the renin-angiotensin system by ethnicity underly the current UK hypertension treatment recommendations [14], and an increase in bradykinin, which occurs with ACEi treatment, has been proposed as contributing to the therapeutic effects of these drugs [17]. Here, KNG1 is linked to hypertensive disorder.